Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 4/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.34 |
| ▸ | MGMT | P16455 | 3/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.34 |
| ▸ | PNP | P00491 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733392 | 0.83 | ADORA2B (0.36) | HPRT1ADORA2BADORA2AMGMTCDK1 | |
| SCHEMBL216787 | 0.83 | HPRT1 (0.44) | HPRT1ADORA2BADORA2APNPPDE4A | |
| SCHEMBL6836074 | 0.83 | HPRT1 (0.39) | HPRT1PNP | |
| SCHEMBL9170817 | 0.76 | HPRT1 (0.43) | HPRT1ADORA2BADORA2AMGMTCDK1 | |
| SCHEMBL8921064 | 0.76 | ADORA2B (0.35) | HPRT1ADORA2BADORA2AMGMTCDK1 | |
| SCHEMBL8397617 | 0.75 | HPRT1 (0.47) | HPRT1ADORA2BADORA2ACDK1CCNB1 | |
| SCHEMBL16020626 | 0.74 | HPRT1 (0.43) | HPRT1ADORA2BADORA2AMGMTPNP | |
| SCHEMBL669007 | 0.73 | ADORA2B (0.61) | ADORA2BADORA2AMGMTCDK1CCNB1 | |
| SCHEMBL28071828 | 0.73 | PNP (0.45) | ADORA2BADORA2AMGMTPNPPDE4A | |
| SCHEMBL8918790 | 0.72 | ADORA2B (0.37) | ADORA2BADORA2AMGMTCDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | AVENTIS PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | TYMP, NUDT1, PNP | HPRT1 8/4885ADORA2B 397/4885ADORA2A 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.